Skip to main content
Top
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade

Authors: Dangjun Zhou, Fengjiao Bai, Xinning Zhang, Minggen Hu, Guodong Zhao, Zhiming Zhao, Rong Liu

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

SOX (high mobility group) genes play an important role in a number of developmental processes. Potential roles of SOXs have been demonstrated in various neoplastic tissues as tumor suppressors or promoters depending on tumor status and types. The aim of this study was to investigate the function role of SOXs in the human hepatocellular carcinoma (HCC). The gene expression changes of SOXs in HCC tissues compared with those in noncancerous hepatic tissues were detected using real-time quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) analysis and immunohistochemistry. In addition, we identified the gene SOX10 that was significantly upregulated in HCC by QRT-PCR analysis and immunohistochemistry. Furthermore, we discovered that SOX10 promoted cancer cell proliferation in vitro, and SOX10 expression correlated with elevated β-catenin levels in HCC, and β-catenin function was required for SOX10’s oncogenic effects. Mechanistically, SOX10 facilitates TCF4 to bind to β-catenin and form a stable SOX10/TCF4/β-catenin complex and trans-activate its downstream target gene. SOX10 mutations that disrupt the SOX10-β-catenin interaction partially prevent its function in tumor cells. All in all, SOX10 is a commonly activated tumor promoter that activates Wnt/β-catenin signaling in cancer cells of HCC.
Literature
1.
go back to reference Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39(4):486–92.CrossRefPubMed Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39(4):486–92.CrossRefPubMed
2.
go back to reference Vinas A et al. Mapping of DNA sex-specific markers and genes related to sex differentiation in turbot (Scophthalmus maximus). Mar Biotechnol (NY). 2012;14(5):655–63.CrossRef Vinas A et al. Mapping of DNA sex-specific markers and genes related to sex differentiation in turbot (Scophthalmus maximus). Mar Biotechnol (NY). 2012;14(5):655–63.CrossRef
4.
go back to reference Coco C et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31:71.PubMedCentralCrossRefPubMed Coco C et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31:71.PubMedCentralCrossRefPubMed
5.
go back to reference Zhang W et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008;68(8):2764–72.PubMedCentralCrossRefPubMed Zhang W et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008;68(8):2764–72.PubMedCentralCrossRefPubMed
7.
go back to reference Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007;45(5):1298–305.CrossRefPubMed Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007;45(5):1298–305.CrossRefPubMed
8.
go back to reference Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.CrossRefPubMed Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.CrossRefPubMed
10.
go back to reference Cao JM et al. High mobility group B proteins regulate mesoderm formation and dorsoventral patterning during zebrafish and Xenopus early development. Mech Dev. 2012;129(9–12):263–74.CrossRefPubMed Cao JM et al. High mobility group B proteins regulate mesoderm formation and dorsoventral patterning during zebrafish and Xenopus early development. Mech Dev. 2012;129(9–12):263–74.CrossRefPubMed
11.
go back to reference Marchetti B et al. Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/beta-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci. 2013;37(10):1550–63.PubMedCentralCrossRefPubMed Marchetti B et al. Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/beta-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci. 2013;37(10):1550–63.PubMedCentralCrossRefPubMed
12.
go back to reference Hu S et al. Sox31 is involved in central nervous system anteroposterior regionalization through regulating the organizer activity in zebrafish. Acta Biochim Biophys Sin (Shanghai). 2011;43(5):387–99.CrossRef Hu S et al. Sox31 is involved in central nervous system anteroposterior regionalization through regulating the organizer activity in zebrafish. Acta Biochim Biophys Sin (Shanghai). 2011;43(5):387–99.CrossRef
13.
go back to reference Aksoy I et al. Sox transcription factors require selective interactions with Oct4 and specific transactivation functions to mediate reprogramming. Stem Cells. 2013;31(12):2632–2646. Aksoy I et al. Sox transcription factors require selective interactions with Oct4 and specific transactivation functions to mediate reprogramming. Stem Cells. 2013;31(12):2632–2646.
14.
go back to reference Jiang T et al. The SOX gene family: function and regulation in testis determination and male fertility maintenance. Mol Biol Rep. 2013;40(3):2187–94.CrossRefPubMed Jiang T et al. The SOX gene family: function and regulation in testis determination and male fertility maintenance. Mol Biol Rep. 2013;40(3):2187–94.CrossRefPubMed
15.
go back to reference Goding CR. Melanocyte development and malignant melanoma. Forum (Genova). 2000;10(3):176–87. Goding CR. Melanocyte development and malignant melanoma. Forum (Genova). 2000;10(3):176–87.
16.
go back to reference Soullier S et al. Diversification pattern of the HMG and SOX family members during evolution. J Mol Evol. 1999;48(5):517–27.CrossRefPubMed Soullier S et al. Diversification pattern of the HMG and SOX family members during evolution. J Mol Evol. 1999;48(5):517–27.CrossRefPubMed
17.
go back to reference Argenton F et al. Ectopic expression and knockdown of a zebrafish sox21 reveal its role as a transcriptional repressor in early development. Mech Dev. 2004;121(2):131–42.CrossRefPubMed Argenton F et al. Ectopic expression and knockdown of a zebrafish sox21 reveal its role as a transcriptional repressor in early development. Mech Dev. 2004;121(2):131–42.CrossRefPubMed
18.
go back to reference Pevny LH, Lovell-Badge R. <i> Sox</i> genes find their feet. Curr Opin Genet Dev. 1997;7(3):338–44.CrossRefPubMed Pevny LH, Lovell-Badge R. <i> Sox</i> genes find their feet. Curr Opin Genet Dev. 1997;7(3):338–44.CrossRefPubMed
19.
go back to reference Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227(2):239–55.CrossRefPubMed Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227(2):239–55.CrossRefPubMed
20.
go back to reference Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn. 2010;239(1):56–68.PubMedCentralPubMed Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn. 2010;239(1):56–68.PubMedCentralPubMed
22.
go back to reference Bafico A et al. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell. 2004;6(5):497–506.CrossRefPubMed Bafico A et al. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell. 2004;6(5):497–506.CrossRefPubMed
24.
go back to reference Ying Y, Tao Q. Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers. Epigenetics. 2009;4(5):307–12.CrossRefPubMed Ying Y, Tao Q. Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers. Epigenetics. 2009;4(5):307–12.CrossRefPubMed
25.
go back to reference Franklin MC et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–28.CrossRefPubMed Franklin MC et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–28.CrossRefPubMed
26.
go back to reference Agus DB et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–37.CrossRefPubMed Agus DB et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–37.CrossRefPubMed
27.
go back to reference Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 1999;19(10):6845–57.PubMedCentralPubMed Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 1999;19(10):6845–57.PubMedCentralPubMed
Metadata
Title
SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade
Authors
Dangjun Zhou
Fengjiao Bai
Xinning Zhang
Minggen Hu
Guodong Zhao
Zhiming Zhao
Rong Liu
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1893-1

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine